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ceiving prophylactic therapy experience both higher life-
time costs ($3,542,357) and higher QALYs (18.95) than
patients receiving on-demand therapy ($2,455,268, 15.31).
The ICER was determined to be $298,531/QALY. In the
sensitivity analysis, the ICER was sensitive to the number
of units/kg/yr of factor used per patient, the probability
of arthropathy in years 1 through 5, and the utilities as-
signed. Varying these parameter estimates resulted in an
ICER ranging from $8,315 to $616,158/QALY. CON-
CLUSION: Results from the baseline model indicate that
lifetime prophylactic infusion of factor VIII in patients
with hemophilia is above the generally accepted thresh-
old for cost-effectiveness of $50,000 per QALY. Due to
the model’s sensitivity to the amount of factor used, it is
recommended that pharmacokinetic dosing be explored
to reduce the amount of factor needed to achieve thera-
peutic levels. Research to determine more accurate utili-
ties for persons with hemophilia with and without arth-
ropathy are also needed.
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OBJECTIVES: As low molecular weight heparins
(LMWH)s such as enoxaparin (ENOX) and dalteparin
(DALT) add drug acquisition cost, yet eliminate the need
for activated prothrombin time (aPPT) monitoring com-
pared to unfractionated heparin (UFH), we developed an
economic model to quantify the value of DALT, or
ENOX compared to UFH as cost per clinical event
avoided from an health management organization per-
spective. METHODS: With a hypothetical patient cohort
with confirmed DVT, treatment and clinical outcomes
were modeled using a conventional decision tree over a 6
month timeframe. Treatment with LMWH or UFH con-
tinued for an average of 5 days. Possible clinical events
included thrombocytopenia, major bleed, recurrent VTE,
or death from any cause. Inpatient treatment with UFH
was necessary due to the IV route of administration and
need for apt monitoring. Subcutaneous administration of
LMWHs facilitate early discharge from hospital or treat-
ment in the outpatient setting for the duration. Based on
published sources, we assumed the proportion of patients
receiving LMWH as inpatients, outpatients or with early
discharge were 45%, 30% and 25%, respectively. Drug
efficacy was obtained from a meta-analysis of published
clinical trials. Resource use data associated with drugs
and inpatient and outpatient medical care were obtained
from published sources, treatment guidelines and an ex-
pert physician panel. Medical unit costs (2000 $US) were
obtained from published sources. RESULTS: The base-
line analysis showed DALT and ENOX prevented 28 and
17 clinical events respectively per 1000 patients com-
pared to UFH. The total medical cost per patient treated
with DALT, ENOX and UFH was $3199, $3347, and
$5104, (US$) respectively. Compared to UFH, cost sav-
ings with use of LMWH was attributed to reduced clini-
cal events and fewer hospital days. Sensitivity analysis
showed results were robust. CONCLUSIONS: These fig-
ures indicate that LMWHs provide important improve-
ments with medical cost savings and thus are attractive
both clinically and economically.
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OBJECTIVES: To estimate the cost-effectiveness of the
insulinotropic agent nateglinide vs. metformin using an
epidemiologic risk model that quantifies the relationship
between glucose spikes as measured by 2 hour postpran-
dial blood glucose (2h-BG) and risks for all cause mortal-
ity, acute myocardial infarction (AMI), and stroke in dia-
betic patients. METHODS: We used data from the
DECODE study database (N  22,474, with up 25 years
of follow-up) to estimate parametric failure time models
predicting the risk for death, AMI, and stroke for 2h-BG,
and other CVD risk factors. The risk equations were used
to develop a decision model that projected risks, costs,
and years of life for up to 40 years for men and women
with and without an intervention specifically to control
2h-BG (results for men with 2h-BG 11 mmol/L re-
ported below). Costs included the intervention and the
costs of CVD events. All costs are expressed in Swiss
francs (CHF), and were discounted at 3%. Clinical effi-
cacy was taken from a randomised clinical trial of nateg-
linide versus metformin. RESULTS: When results were
projected for 15, 25, and 40 years, incremental costs
were 9,137, 10,047, 10,133 CHF, respectively (1 CHF 
$0.60). Discounted years of life saved for these same in-
tervals were 0.15, 0.24, and 0.26. The ratios of cost per
year of life saved were 59,600, 41,500, 38,400 CHF.
CONCLUSIONS: Initial modeling suggests that therapy
with nateglinide among individuals with elevated levels
of 2h-BG reduces the risk for death and CVD events and
has acceptable cost-effectiveness ratios compared to met-
formin.
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